Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
This is a single arm, open label, multicenter extension study in participants who completed treatment period with ocrelizumab in the Roche P-trials. Participants will receive treatment with ocrelizumab as single 600 mg infusions every 24 weeks for two years.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed Informed Consent Form
Able to comply with the study protocol, in the investigator's judgment
Completed the treatment period of Roche sponsored ocrelizumab P-trials
You may not be if
Hypersensitivity to ocrelizumab or to any of its excipients.
Participantss in a severely immunocompromised state until the condition resolves.
Evidence of any adverse event potentially attributable to ocrelizumab, for which the local label recommends permanent discontinuation.
Existence of a contra-indication as per SmPC
Prohibited concomitant medication as specified in protocol
Participants intending to become pregnant during the study or within 6 months after the last dose of the study drug in the parent study
Clareo Health | This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
